198 related articles for article (PubMed ID: 21986113)
1. Cationic ligand appended nanoconstructs: a prospective strategy for brain targeting.
Agarwal A; Agrawal H; Tiwari S; Jain S; Agrawal GP
Int J Pharm; 2011 Dec; 421(1):189-201. PubMed ID: 21986113
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
Jain A; Agarwal A; Majumder S; Lariya N; Khaya A; Agrawal H; Majumdar S; Agrawal GP
J Control Release; 2010 Dec; 148(3):359-67. PubMed ID: 20854859
[TBL] [Abstract][Full Text] [Related]
3. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
Lu W; Wan J; She Z; Jiang X
J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
[TBL] [Abstract][Full Text] [Related]
4. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles.
Xu F; Lu W; Wu H; Fan L; Gao X; Jiang X
J Drug Target; 2009 Jul; 17(6):423-34. PubMed ID: 19527113
[TBL] [Abstract][Full Text] [Related]
5. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier.
Lu W; Tan YZ; Hu KL; Jiang XG
Int J Pharm; 2005 May; 295(1-2):247-60. PubMed ID: 15848009
[TBL] [Abstract][Full Text] [Related]
6. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
7. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting.
Nimje N; Agarwal A; Saraogi GK; Lariya N; Rai G; Agrawal H; Agrawal GP
J Drug Target; 2009 Dec; 17(10):777-87. PubMed ID: 19938949
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
Pandey V; Gajbhiye KR; Soni V
Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
11. New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles.
Mussi SV; Silva RC; Oliveira MC; Lucci CM; Azevedo RB; Ferreira LA
Eur J Pharm Sci; 2013 Jan; 48(1-2):282-90. PubMed ID: 23178339
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
[TBL] [Abstract][Full Text] [Related]
13. Intracellular delivery mechanism and brain delivery kinetics of biodegradable cationic bovine serum albumin-conjugated polymersomes.
Pang Z; Gao H; Chen J; Shen S; Zhang B; Ren J; Guo L; Qian Y; Jiang X; Mei H
Int J Nanomedicine; 2012; 7():3421-32. PubMed ID: 22848168
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.
Tian Q; Zhang CN; Wang XH; Wang W; Huang W; Cha RT; Wang CH; Yuan Z; Liu M; Wan HY; Tang H
Biomaterials; 2010 Jun; 31(17):4748-56. PubMed ID: 20303163
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
16. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
17. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
Benival DM; Devarajan PV
Int J Pharm; 2012 Feb; 423(2):554-61. PubMed ID: 22155412
[TBL] [Abstract][Full Text] [Related]
18. An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery.
Li S; Su Z; Sun M; Xiao Y; Cao F; Huang A; Li H; Ping Q; Zhang C
Int J Pharm; 2012 Oct; 436(1-2):248-57. PubMed ID: 22732672
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
20. [Preparation of doxorubicin-loaded chitosan polymeric micelle and study on its tissue biodistribution in mice].
Xu XY; Zhou JP; Li L; Zhang Y; Huo MR; Wang X; Lü L
Yao Xue Xue Bao; 2008 Jul; 43(7):743-8. PubMed ID: 18819480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
